Granulocytic sarcoma
You don't need to be Editor-In-Chief to add or edit content to WikiDoc. You can begin to add to or edit text on this WikiDoc page by clicking on the edit button at the top of this page. Next enter or edit the information that you would like to appear here. Once you are done editing, scroll down and click the Save page button at the bottom of the page.
| Chloroma Classification and external resources | |
 | |
|---|---|
| Lymph node: Granulocytic sarcoma. Image courtesy of Professor Peter Anderson DVM PhD and published with permission © PEIR, University of Alabama at Birmingham, Department of Pathology | |
| ICD-10 | C92.3 |
| ICD-9 | 205.3 |
| ICD-O: | 9930/3 |
| MeSH | D023981 |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Phone:617-525-6884
Please Take Over This Page and Apply to be Editor-In-Chief for this topic: There can be one or more than one Editor-In-Chief. You may also apply to be an Associate Editor-In-Chief of one of the subtopics below. Please mail us [2] to indicate your interest in serving either as an Editor-In-Chief of the entire topic or as an Associate Editor-In-Chief for a subtopic. Please be sure to attach your CV and or biographical sketch.
Overview
A chloroma, or granulocytic sarcoma, or most appropriately, extramedullary myeloid tumor, is a solid tumor composed of immature malignant white blood cells called myeloblasts. A chloroma is an extramedullary manifestion of acute myeloid leukemia; in other words, it is a solid collection of leukemic cells occurring outside of the bone marrow.
History
The condition now known as chloroma was first described by the British physician A. Burns in 1811[1], although the term chloroma did not appear until 1853.[1] This name is derived from the Greek word chloros (green), as these tumors often have a green tint due to the presence of myeloperoxidase. The link between chloroma and acute leukemia was first recognized in 1902 by Dock and Warthin.[1] However, because up to 30% of these tumors can be white, gray, or brown rather than green, the more correct term granulocytic sarcoma was proposed by Rappaport in 1967[1] and has since become virtually synonymous with the term chloroma.
Currently, any extramedullary manifestion of acute myeloid leukemia can be termed a granulocytic sarcoma or chloroma. Specific terms which overlap with granulocytic sarcoma include:
- Leukemia cutis, describing infiltration of the dermis (skin) by leukemic cells, which is also referred to as cutaneous granulocytic sarcoma.
- Meningeal leukemia, or invasion of the subarachnoid space by leukemic cells, is usually considered distinct from chloroma, although very rarely occurring solid central nervous system tumors composed of leukemic cells can be termed chloromas.
Frequency and patterns of presentation
In acute leukemia
Chloromas are rare; exact estimates of their incidence are lacking, but they are uncommonly seen even by physicians specializing in the treatment of leukemia. Chloromas may be somewhat more common in patients with the following disease features:[1]
- FAB class M4 or M5
- those with specific cytogenetic abnormalities (e.g. t(8;21) or inv(16))
- those whose myeloblasts express T-cell surface markers, CD13, or CD14
- those with high peripheral white blood cell counts
However, even in patients with the above risk factors, chloroma remains an uncommon complication of acute myeloid leukemia.
Rarely, a chloroma can develop as the sole manifestation of relapse after apparently successful treatment of acute myeloid leukemia. In keeping with the general behavior of chloromas, such an event must be regarded as an early herald of a systemic relapse, rather than as a localized process. In one review of 24 patients who developed isolated chloromas after treatment for acute myeloid leukemia, the mean interval until bone marrow relapse was 7 months (range, 1 to 19 months).[1]
In myeloproliferative or myelodysplastic syndromes
Chloromas may occur in patients with a diagnosis of myelodysplastic syndrome (MDS) or myeloproliferative syndromes (MPS) (e.g. chronic myelogenous leukemia (CML), polycythemia vera, essential thrombocytosis, or myelofibrosis). The detection of a chloroma is considered de facto evidence that these pre-malignant conditions have transformed into an acute leukemia requiring appropriate treatment. For example, presence of a chloroma is sufficient to indicate that chronic myelogenous leukemia has entered its blast crisis phase.
Primary chloroma
Very rarely, chloroma can occur without a known pre-existing or concomitant diagnosis of acute leukemia or MDS/MPS; this is known as primary chloroma. Diagnosis is particularly challenging in this situation (see below). In almost all reported cases of primary chloroma, acute leukemia has developed shortly afterward (median time to development of acute leukemia 7 months, range 1-25 months).[1] Therefore, primary chloroma should probably be considered an initial manifestation of acute leukemia, rather than a localized process, and treated as such.
Location and symptoms
Chloromas may occur in virtually any organ or tissue. The most common areas of involvement are the skin (also known as leukemia cutis) and the gums. Skin involvement typically appears as violaceous, raised, nontender plaques or nodules, which on biopsy are found to be infiltrated with myeloblasts. Note that leukemia cutis differs from Sweet's syndrome, in which the skin is infiltrated by mature neutrophils in a paraneoplastic process. Gum involvement (gingival hypertrophy) leads to swollen, sometimes painful gums which bleed easily with tooth brushing and other minor trauma.
Other tissues which can be involved include lymph nodes, the small intestine, the mediastinum, epidural sites, the uterus, and the ovaries. Symptoms of chloroma at these sites are related to their anatomic location; chloromas may also be asymptomatic and be discovered incidentally in the course of evaluation of a person with acute myeloid leukemia.
Central nervous system involvement, as described above, most often takes the form of meningeal leukemia, or invasion of the subarachnoid space by leukemic cells. This condition is usually considered separately from chloroma, as it requires different treatment modalities. True chloromas (i.e. solid leukemic tumors) of the central nervous system are exceedingly rare, but has been described.
Diagnosis
Definitive diagnosis of a chloroma usually requires a biopsy of the lesion in question. Historically, even with a tissue biopsy, pathologic misdiagnosis was an important problem, particularly in patients without a clear pre-existing diagnosis of acute myeloid leukemia to guide the pathologist. In one published series on chloroma, the authors stated that 47% of the patients were initially misdiagnosed, most often as having a malignant lymphoma.[1]
However, with advances in diagnostic techniques, the diagnosis of chloromas can be made more reliable. Traweek et al. described the use of a commercially available panel of monoclonal antibodies, against myeloperoxidase, CD68, CD43, and CD20, to accurately diagnose chloroma via immunohistochemistry and differentiate it from lymphoma.[1] The increasingly refined use of flow cytometry has also facilitated more accurate diagnosis of these lesions.
Prognostic significance
There is conflicting evidence on the prognostic significance of chloromas in patients with acute myeloid leukemia. In general, they are felt to augur a poorer prognosis, with a poorer response to treatment and worse survival[1]; however, others have reported that chloromas associate, as a biologic marker, with other poor prognostic factors, and therefore do not have independent prognostic significance.[1]
Treatment
As described above, chloromas should always be considered manifestations of systemic disease, rather than isolated local phenomena, and treated as such. In the patient with newly diagnosed leukemia and an associated chloroma, systemic chemotherapy against the leukemia is typically utilized as the first-line treatment, unless there is an emergent indication for local treatment of the chloroma (e.g. compromise of the spinal cord). Chloromas are typically quite sensitive to standard anti-leukemic chemotherapy.
If the chloroma is persistent after completion of induction chemotherapy, local treatment such as surgery or radiation therapy is often considered.
Patients presenting with a primary chloroma typically receive systemic chemotherapy, as development of acute leukemia is nearly universal in the short term after detection of the chloroma.
Patients treated for acute leukemia who relapse with an isolated chloroma are typically treated with systemic therapy for relapsed leukemia. However, as with any relapsed leukemia, outcomes are unfortunately poor.
Patients with "pre-leukemic" conditions such as myelodysplastic syndromes or myeloproliferative syndromes who develop a chloroma are often treated as if they have transformed to acute leukemia.
References
See also
WikiDoc Research Resources for Granulocytic sarcoma | |
|---|---|
| Articles on Granulocytic sarcoma | Most recent articles on Granulocytic sarcoma • Most cited articles on Granulocytic sarcoma • Review articles on Granulocytic sarcoma • Articles on Granulocytic sarcoma in N Eng J Med, Lancet, BMJ |
| Media (Slides, Video, Images, MP3) on Granulocytic sarcoma | Powerpoint slides on Granulocytic sarcoma • Images of Granulocytic sarcoma • Photos of Granulocytic sarcoma • Podcasts & MP3s on Granulocytic sarcoma • Videos on Granulocytic sarcoma |
| Evidence Based Medicine Regarding Granulocytic sarcoma | Cochrane Collaboration on Granulocytic sarcoma • Bandolier on Granulocytic sarcoma • TRIP on Granulocytic sarcoma |
| Cost Effectiveness of Granulocytic sarcoma | Cost Effectiveness of Granulocytic sarcoma |
| Clinical Trials Involving Granulocytic sarcoma | Ongoing Trials on Granulocytic sarcoma at Clinical Trials.gov • Trial results on Granulocytic sarcoma • Clinical Trials on Granulocytic sarcoma at Google |
| Guidelines / Policies / Government Resources (FDA/CDC) Regarding Granulocytic sarcoma | US National Guidelines Clearinghouse on Granulocytic sarcoma • NICE Guidance on Granulocytic sarcoma • NHS PRODIGY Guidance • FDA on Granulocytic sarcoma • CDC on Granulocytic sarcoma |
| Textbook Information on Granulocytic sarcoma | Books and Textbook Information on Granulocytic sarcoma |
| Pharmacology Resources on Granulocytic sarcoma | Dosing of Granulocytic sarcoma • Drug interactions with Granulocytic sarcoma • Side effects of Granulocytic sarcoma • Allergic reactions to Granulocytic sarcoma • Overdose information on Granulocytic sarcoma • Carcinogenicity information on Granulocytic sarcoma • Granulocytic sarcoma in pregnancy • Pharmacokinetics of Granulocytic sarcoma • |
| Genetics, Pharmacogenomics, and Proteinomics of Granulocytic sarcoma | Genetics of Granulocytic sarcoma • Pharmacogenomics of Granulocytic sarcoma • Proteomics of Granulocytic sarcoma |
| Newstories on Granulocytic sarcoma | Granulocytic sarcoma in the news • Be alerted to news on Granulocytic sarcoma • News trends on Granulocytic sarcoma |
| Commentary on Granulocytic sarcoma | Blogs on Granulocytic sarcoma |
| Patient Resources on Granulocytic sarcoma | Patient resources on Granulocytic sarcoma • Discussion groups on Granulocytic sarcoma • Patient Handouts on Granulocytic sarcoma • Directions to Hospitals Treating Granulocytic sarcoma • Risk calculators and risk factors for Granulocytic sarcoma |
| Healthcare Provider Resources on Granulocytic sarcoma | Symptoms of Granulocytic sarcoma • Causes & Risk Factors for Granulocytic sarcoma • Diagnostic studies for Granulocytic sarcoma • Treatment of Granulocytic sarcoma |
| Continuing Medical Education (CME) Programs on Granulocytic sarcoma | CME Programs on Granulocytic sarcoma |
| International Resources on Granulocytic sarcoma | Granulocytic sarcoma en Espanol • Granulocytic sarcoma en Francais |
| Business Resources on Granulocytic sarcoma | Granulocytic sarcoma in the Marketplace • Patents on Granulocytic sarcoma |
| Informatics Resources on Granulocytic sarcoma | List of terms related to Granulocytic sarcoma |
| ||||
Acknowledgement and Attribution Regarding Sources of Content
Some of the initial content on this page may be incorporated in part from copyleft sources in the public domain including wikis such as Wikipedia and AskDrWiki. Drug information for patients came from the The National Library of Medicine. Infectious disease information may have come from the Centers for Disease Control (CDC). Differential Diagnoses are drawn from clinicians as well as an amalgamation of 3 sources: 1.The Disease Database; 2. Kahan, Scott, Smith, Ellen G. In A Page: Signs and Symptoms. Malden, Massachusetts: Blackwell Publishing, 2004:3; 3. Sailer, Christian, Wasner, Susanne. Differential Diagnosis Pocket. Hermosa Beach, CA: Borm Bruckmeir Publishing LLC, 2002:7 .
